Strategies to develop a prophylaxis for the prevention of HPA-1a immunization and fetal and neonatal alloimmune thrombocytopenia

Mette Kjær, Christof Geisen, Çiğdem Akalın Akkök, Agneta Wikman, Ulrich Sachs, James B Bussel, Kaspar Nielsen, Katarina Walles, Brian R Curtis, Gestur Vidarsson, Kerstin Järås, Bjørn Skogen

Publikation: Bidrag til tidsskriftReview (oversigtsartikel)peer review

14 Citationer (Scopus)
85 Downloads (Pure)

Abstract

Anti-HPA-1a-antibodies are the main cause of fetal and neonatal alloimmune thrombocytopenia (FNAIT) which may result in intracranial hemorrhage (ICH) and death among fetuses and newborns. Advances in understanding the pathogenesis of FNAIT and proof of concept for prophylaxis to prevent immunization suggest that development of hyperimmune anti-HPA-1a IgG aimed at preventing immunization against HPA-1a and FNAIT is feasible. Anti-HPA-1a IgG can be obtained either by isolating immunoglobulin from already-immunized women or by development of monoclonal anti-HPA-1a antibodies. Here we discuss recent advances that may lead to the development of a prenatal and postnatal prophylactic treatment for the prevention of HPA-1a-associated FNAIT and life-threatening FNAIT-induced complications.

OriginalsprogEngelsk
Artikelnummer102712
TidsskriftTransfusion and Apheresis Science
Vol/bind59
Udgave nummer1
Antal sider6
ISSN1473-0502
DOI
StatusUdgivet - 2020

Fingeraftryk

Dyk ned i forskningsemnerne om 'Strategies to develop a prophylaxis for the prevention of HPA-1a immunization and fetal and neonatal alloimmune thrombocytopenia'. Sammen danner de et unikt fingeraftryk.

Citationsformater